UTRECHT, The Netherlands and
CAMBRIDGE, Massachusetts,
June 14, 2016 /PRNewswire/ --
New Fund Targets Innovative Scale-up
Opportunities in Medtech, Digital Health and
Therapeutics
Gilde Healthcare, the European specialist investment firm, today
announces the final close of Gilde Healthcare IV, a €250 million
($285 million) later stage and growth
capital fund. The new fund, which was oversubscribed, is targeting
investments in innovative private scale-up opportunities in
medtech, digital health and therapeutics both in Europe and North
America.
Gilde Healthcare IV, which closed at its hard cap, is backed by
a balanced mix of international investors. Royal Philips (NYSE: PHG, AEX: PHIA) acted as a
cornerstone investor, extending the collaboration which started in
the previous Gilde Healthcare III fund. Johnson & Johnson
Innovation - JJDC, Inc. joined as a new corporate investor in Gilde
Healthcare IV. Additional investors include fund-of-funds,
sovereign funds such as Danish Growth Fund, endowments, family
offices, entrepreneurs and Gilde partners. The European Investment
Fund participated in the fund through several of its funding
programs including the European Recovery Program and Dutch Venture
Initiative II.
Investors have been attracted by Gilde Healthcare's strong track
record. In the last three years, Gilde exited 14 portfolio
companies across its healthcare funds realizing significant value
for its investors. Amongst the companies that were successfully
divested over this period are Definiens, the leading provider of
image analysis software for digital pathology; Inovalabs, which
markets portable oxygen concentrators for patients with respiratory
conditions; ProFibrix, which developed a novel topical hemostatic
agent to treat fast bleeding wounds; Prosonix, a speciality
pharmaceutical company developing a portfolio of inhaled
respiratory medicines by design; Santaris, which develops
RNA-targeted drugs and Sapiens, a Dutch neuro-modulation company
focused on deep brain stimulation for patients suffering from
Parkinson's disease.
Pieter van der Meer, Managing
Partner, Gilde Healthcare commenting on today's release said, "The
healthcare landscape in the US and Europe is changing, driven by the need for
more patient centric care and a much sharper focus on value. With
our new fund we will continue to pursue our differentiated
investment strategy of backing growth and later stage companies
developing novel technologies or therapeutics that enable better
healthcare outcomes at reduced costs."
Gilde Healthcare's hands-on investment team, which is based on
both sides of the Atlantic, actively supports the international
growth of its companies. The Gilde Healthcare IV Fund will make
equity investments in a single portfolio company of between €15-25
million.
About Gilde Healthcare
Gilde Healthcare is based in Utrecht,
The Netherlands and Cambridge,
Massachusetts. The firm is organized along two business
lines managing separate funds for innovative healthcare technology
companies and lower mid-market healthcare services companies.
Gilde has raised over €800 million ($910
million) in dedicated healthcare funds and is actively
looking to lead new private investments in medtech, digital health,
therapeutics and healthcare services.
For a list of Gilde Healthcare's portfolio companies please
visit the website at http://www.gildehealthcare.com
Media Contacts
Gilde Healthcare
Pieter van der Meer
Managing Partner
T +31 30 219 2533
E vandermeer@gildehealthcare.com
Citigate Dewe Rogerson
Katja Stout/Sylvie Berrebi
T + 44 020 7282 1052
E sylvie.berrebi@citigatedr.co.uk
Citigate First Financial, the Netherlands
Marieke Heringa - van Kruiningen
T + 31 20 575 40 14
M + 31 6 11 32 75 33
E marieke.heringa@citigateff.nl
SOURCE Gilde Healthcare